This is crazy - we are post positive results in p2, deal in hand with scope for more from RoW and we have lost value from pre deal - we are lower than pre p2 results if memory serves me correctly.
I don't understand this stock because on fundamentals, for a p3 ready drug, with a seemingly easy (and repeatable) results, we should be multiples of our current price.
I made this point recently on a thread - this seems to be purely a result of the market we trade in. i cant see any reason why we are not climbing in terms of SP. If we were listed in the US I think it would be a different story.
At least that is the only logical conclusion I can come to.
Ann: Plans for Phase 3 trial in Rett syndrome, page-28
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.11 |
Change
-0.090(0.63%) |
Mkt cap ! $1.750B | |||
| Open | High | Low | Value | Volume |
| $14.23 | $14.71 | $14.01 | $6.213M | 438.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7700 | $14.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.16 | 3278 | 1 |
View Market Depth
| Last trade - 16.16pm 30/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |